Studies have shown that a higher number of FOXP3-positive Tregs identifies patients with BC with no recurrence and shorter OS, suggesting that Tregs may impede anti-tumor immune responses (33, 74, 75). This evidence concerns the gene FOXP3 and neoplasm.